An underground economy for unapproved weight-loss drugs is being driven by social media fitness personalities and vendors on communication apps, based on new investigations.
Investigational Treatment Gaining Traction Via Social Media
The experimental drug, which is still in clinical trials, is being advertised by online personalities for its supposed weight-reducing effects. Followers are urged to message these profiles directly for source information, while also obtaining discount codes.
Active Commerce on Social Networks
Additionally, a flourishing market exists on messaging services, where communities with thousands of members share comparison images, administration instructions and claims of rapid UK delivery. Vendors promote the drug there before redirecting buyers to other platforms for transactions.
Understanding The Experimental Drug
Retatrutide is an investigational injectable created by American pharmaceutical company Eli Lilly. The drug affects three intestinal hormones – GLP-1, GIP and pancreatic hormone. Early trials suggest it could assist patients lose up to 25% of their body weight. Referred to as the “triple G”, the drug is being promoted digitally as the successor to Ozempic.
Healthcare Experts Express Concerns
Nevertheless, physicians and pharmacists have warned that the sale of what remains an unlicensed medication in the United Kingdom is a cause for concern and could result in users administering products of unknown origin.
Several professionals said the demand for the experimental drug could be connected to the rising cost of licensed weight loss products such as Mounjaro.
Regulatory Status and Implementation
Marketing the unapproved drug on TikTok or messaging apps is prohibited in the United Kingdom, as it is an unapproved medication that must not be marketed or distributed for personal consumption under the Human Medicines Regulations 2012.
Some influencers try to circumvent the regulations by calling to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted substance, but promotion and distribution can still breach pharmaceutical, marketing, and consumer regulations, risking fines, prosecution or imprisonment.
Service Response and Content Elimination
According to the social media company, the service has removed violative material and banned related keywords and query recommendations. The organization said it was committed to keeping the platform secure and allocating resources in strengthening enforcement strategies.
Digital Marketplace Operations
Research also discovered communities with up to 9,000 participants selling retatrutide using Telegram's integrated search feature, which functions like a public directory. Entering “retatrutide” instantly displays groups with thousands of users, populated with images of slimming results, glowing reviews and step-by-step guides for preparing or administering at home.
After minutes of entering one community, a seller shared WhatsApp details, where most transactions take place. The vendor provided an guidebook and guaranteed shipping within two days. When questioned whether the substance was genuine, one vendor said: “You can’t be sure.” Another provided a photo of a supposed testing documentation. None inquired about body mass, medical conditions or previous experience.
Product Details and Costs
Within these communities, messages display black plastic parcels with Royal Mail labels, stating to contain new batches. One communication read: “It took eight of us to load them this morning.”
Buyers can select between dry substance containers, prepared at residence with sterile water, or pre-filled pens usually priced at £160 for 20mg. When questioned how long a injector should be used, vendors give conflicting responses varying between a several days to “depends on your body”.
Platform Moderation and Security Measures
A representative for the messaging service said it regularly moderated harmful material on its platform including content that promoted the “misuse of controlled medications”. The organization noted that it eliminated “millions of pieces of harmful content each day”.
Medical Professional Cautions
“People are administering substances they can’t verify. Even if the science behind this drug is valid, these digital versions may not include what they claim,” stated Jason Murphy, the director of pharmacy at Chemist4U.
A medical professional of an online medical service linked the increase in demand to current cost increases for authorized slimming drugs such as Mounjaro. “With prices increasing, patients are turning to social media. But counterfeit injections are extremely risky. You cannot know what’s inside or whether the environment they were produced in was sterile,” she explained.
Her team has already seen individuals injured by self-injection from unverified suppliers. “We recognize the disappointment, but purchasing from messaging apps or WhatsApp is gambling with your health,” stated Wyllie. “These materials could be contaminated or incorrectly dosed.”
Producer Statement
A spokesperson from the pharmaceutical company said retatrutide was in phase 3 clinical trials and had not been reviewed or approved by any government authority anywhere in the world. “Consequently at this point no one can sell [it] for human use,” they explained, adding that any item “falsely representing itself as a company investigational product not yet approved … may subject patients to possibly serious health risks”.
